Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes
Articolo
Data di Pubblicazione:
2020
Citazione:
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes / Maffi, Paola; Lundgren, Torbjörn; Tufveson, Gunnar; Rafael, Ehab; Shaw, James A M; Liew, Aaron; Saudek, Frantisek; Witkowski, Piotr; Golab, Karolina; Bertuzzi, Federico; Gustafsson, Bengt; Daffonchio, Luisa; Ruffini, Pier Adelchi; Piemonti, Lorenzo. - In: DIABETES CARE. - ISSN 0149-5992. - 43:4(2020), pp. 710-718. [10.2337/dc19-1480]
Abstract:
Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allo-transplant recipients.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Maffi, Paola; Lundgren, Torbjörn; Tufveson, Gunnar; Rafael, Ehab; Shaw, James A M; Liew, Aaron; Saudek, Frantisek; Witkowski, Piotr; Golab, Karolina; Bertuzzi, Federico; Gustafsson, Bengt; Daffonchio, Luisa; Ruffini, Pier Adelchi; Piemonti, Lorenzo
Link alla scheda completa:
Pubblicato in: